Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen reported record Q3 2026 revenue of $209.3 million, up 11% as reported and 12.5% organically, with adjusted EPS of $0.53 versus $0.46 a year ago. The company closed its acquisition of BioLife Solutions on October 6, adding a recurring-revenue cell-therapy consumables platform, and opened a new Training & Innovation Center in Seoul. Full-year 2026 guidance was raised to $844M-$852M in revenue (14.5%-15.5% reported growth) with adjusted diluted EPS of $2.05-$2.09.
Key figures
- Revenue
- 209314000
- Guidance
- FY26 revenue $844M-$852M (reported growth 14.5%-15.5%), organic growth 12%-13%, adjusted diluted EPS $2.05-$2.09
- Revenue Yoy
- 11%
- Adjusted eps
- 0.53
- Organic growth
- 12.5%
- Intangible impairment
- 41242000
- Adjusted ebitda margin
- 20.9%
- Adjusted eps prior year
- 0.46
- Ytd operating cash flow
- 104160000
- Adjusted operating income
- 33288000
- Cash and marketable securities
- 863000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.